Compounds
Patent
US-2020002323-A1
Inventor
CUI HAIFENG (US)
REN FENG (CN)
SANG YINGXIA (CN)
ZHANG XIAOMIN (CN)
Assignee
GLAXOSMITHKLINE IP DEV LTD (GB)
Country
United States
Dates
- Priority:2017/01/25
Description
This web page summarizes information in PubChem about patent US-2020002323-A1. This includes chemicals mentioned, as reported by PubChem contributors, as well as other content, such as title, abstract, and International Patent Classification (IPC) codes. To read more about how this page was constructed, please visit the PubChem patents help page.
Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
2017/01/25
2018/01/23
2020/01/02
CUI HAIFENG (US)
REN FENG (CN)
SANG YINGXIA (CN)
ZHANG XIAOMIN (CN)
GLAXOSMITHKLINE IP DEV LTD (GB)
United States
C07D401/14 (inventive)
A61P25/16 (inventive)
C07D413/14 (inventive, first)
A61P25/16 (inventive)
C07D413/14 (inventive, first)
C07D401/14 (inventive)
- US-10858367-B2 (SEA)
- US-11867057-B2 (APP)
- Google PatentsLICENSE"Google Patents Research Data" by Google, based on data provided by IFI CLAIMS Patent Services and OntoChem, is licensed under a Creative Commons Attribution 4.0 International License.https://creativecommons.org/licenses/by/4.0/legalcode
- PubChem
CONTENTS